Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
Adaptive Biotechnologies achieved total company profitability in the third quarter of 2026, reporting $83.9 million in revenue and raising its full-year MRD revenue guidance.
Stocks · News reference
Telo Genomics Expands Comparative Evaluation of TELO-MRD Against Adaptive Biotechnologies' clonoSEQ
Telo Genomics is advancing clinical research initiatives to compare its blood-based TELO-MRD assay against Adaptive Biotechnologies' clonoSEQ next-generation sequencing MRD testing.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Adaptive Biotechnologies Q3 Adj. EPS $(0.13) Misses $(0.10) Estimate, Sales $83.902M Beat $71.600M Estimate
Adaptogenics Health Corp. Engages InvestorBrandNetwork for Corporate Communications Strategy
Adaptogenics Health Corp. has partnered with InvestorBrandNetwork (IBN) to enhance its corporate communications and investor outreach strategy.
Adaptogenics Health Corp. Announces Upcoming Annual General and Special Meeting
Adaptogenics Health Corp. has scheduled its Annual General and Special (AGS) meeting for December 18, 2026, with a record date of November 13, 2026.
Adaptive Biotechnologies Insider Sold Shares Worth $879,088
An insider at Adaptive Biotechnologies Corporation has sold company shares valued at approximately $879,088.
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32
TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $28 to $32.